



Dedicated To Life

November 28, 2022

Listing Department  
**BOMBAY STOCK EXCHANGE LIMITED**  
P J Towers, Dalal Street, Fort,  
Mumbai-400 001

Code: **532321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

Code: **ZYDUSLIFE**

Re.: **Press Release**

Dear Sir / Madam,

Please find enclosed a copy of press release dated November 28, 2022, titled "**Zydus receives tentative approval from the USFDA for Levothyroxine Sodium for Injection**".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,  
For, **ZYDUS LIFESCIENCES LIMITED**

**DHAVAL N. SONI**  
**COMPANY SECRETARY**

**Encl.:** As above

**Zydus Lifesciences Limited** (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : [www.zyduslife.com](http://www.zyduslife.com) | CIN : L24230GJ1995PLC025878



## **Zydus receives tentative approval from the USFDA for Levothyroxine Sodium for Injection**

*Ahmedabad, India, 28 November, 2022*

Zydus Lifesciences Limited's (formerly known as Cadila Healthcare Limited) U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the United States Food and Drug Administration (USFDA) to market Levothyroxine Sodium for injection, 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial (USRLD: Levothyroxine Sodium injection manufactured by Fresenius Kabi USA, LLC).

Levothyroxine Sodium injection is indicated for the treatment of myxedema coma. The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India.

Levothyroxine Sodium injection had annual sales of USD 45.2 mn in the United States according to IQVIA data (IQVIA MAT Sep 2022).

The group now has 334 approvals and has so far filed over 431\* ANDAs since the commencement of the filing process in FY 2003-04.

*(\*as of 30<sup>th</sup> September 2022)*

\*\*\*



**PRESS  
RELEASE**

For further information please contact :  
**The Corporate Communications Department**

**Zydus Lifesciences Limited**  
(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park',  
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),  
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382  
481, Gujarat, India. | Phone : +91-79-71800000,  
+91-79-48040000 | website : [www.zyduslife.com](http://www.zyduslife.com)  
CIN : L24230GJ1995PLC025878